ClinicalTrials.gg

Program

orevandrodeg

Its studies are mostly in Prostatic Neoplasms, led by Bristol-Myers Squibb.

Furthest: phase 1, since Sep 28, 20232 company-led studies, 1 open or runningNext primary completion: Aug 24, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb21 open or runningphase 1since Sep 28, 2023Sep 28, 2023Aug 24, 2029phase 1 · NCT06067841
  • Named in Bristol-Myers Squibb’s own pipeline as BMS-986460, phase 1, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2023First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT06067841 · 140 planned · United States, Canada, France
  2. Mar 10, 2025Phase 1 study in Healthy VolunteersNCT06877702 · 85 enrolled · United States

Ahead

  1. Aug 24, 2029Primary completion: phase 1 study in Prostatic NeoplasmsNCT06067841

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06877702Healthy Volunteers · United States1CompletedDec 17, 202585
NCT06067841Prostatic Neoplasms · United States, Canada, France1RecruitingAug 24, 2029140

How it is read

Names in the registry

  • “BMS-986460”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.